Brief: Eagle Pharmaceuticals Announces FDA Acceptance Of Investigational New Drug For The Treatment Of Pneumonia
14/11/2022 12:03
Nov 14 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF
INVESTIGATIONAL NEW DRUG APPLICATION FOR CAL02, A NOVEL
FIRST-IN-CLASS BROAD-SPECTRUM ANTI-VIRULENCE AGENT FOR THE
ADJUNCT TREATMENT OF SEVERE COMMUNITY-ACQUIRED BACTERIAL
PNEUMONIA
* EAGLE PHARMACEUTICALS INC - PATIENT ENROLLMENT EXPECTED TO
COMMENCE AS EARLY AS BEGINNING OF 2023
* EAGLE PHARMACEUTICALS - EXPECT TO BEGIN A PHASE 2 STUDY IN
ABOUT
276 PATIENTS WITH SEVERE COMMUNITY-ACQUIRED PNEUMONIA AT ABOUT
120 SITES WORLDWIDE
* EAGLE PHARMACEUTICALS INC - CAL02 IS BEING DEVELOPED AS AN
ADJUNCT TO CLINICALLY INDICATED ANTIBIOTIC TREATMENT
Source text for Eikon: ID:nGNX5fmLkJ
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq